Literature DB >> 16019000

Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration.

Imran A Bhutto1, D Scott McLeod, Takuya Hasegawa, Sahng Y Kim, Carol Merges, Patrick Tong, Gerard A Lutty.   

Abstract

The purpose of this study was to examine the localization and relative levels of vascular endothelial growth factor (VEGF; an angiogenic factor) and pigment epithelium-derived factor (PEDF; an antiangiogenic factor) in aged human choroid and to determine if the localization or their relative levels changed in age-related macular degeneration (AMD). Ocular tissues were obtained from eight aged control donors (age range, 75-86 years; mean age, 79.8 years) with no evidence or history of chorioretinal disease and from 12 donors diagnosed with AMD (age range, 61-105 years; mean age, 83.9 years). Tissues were cryopreserved and streptavidin alkaline phosphatase immunohistochemistry was performed with rabbit polyclonal anti-human VEGF and rabbit polyclonal anti-human PEDF antibodies. Binding of the antibodies was blocked by preincubation of the antibody with an excess of recombinant human PEDF or VEGF peptide. Choroidal blood vessels were identified with mouse anti-human CD-34 antibody in adjacent tissue sections. Three independent observers graded the immunohistochemical reaction product. The most prominent sites of VEGF and PEDF localization in aged control choroid were RPE-Bruch's membrane-choriocapillaris complex including RPE basal lamina, intercapillary septa, and choroidal stroma. There was no significant difference in immunostaining intensity and localization of VEGF and PEDF in aged control choroids. The most intense VEGF immunoreactivity was observed in leukocytes within blood vessels. AMD choroid had a similar pattern and intensity of VEGF immunostaining to that observed in aged controls. However, PEDF immunoreactivity was significantly lower in RPE cells (p=0.0073), RPE basal lamina (p=0.0141), Bruch's membrane (p<0.0001), and choroidal stroma (p=0.0161) of AMD choroids. The most intense PEDF immunoreactivity was observed in disciform scars. Drusen and basal laminar deposits (BLDs) were positive for VEGF and PEDF. In aged control subjects, VEGF and PEDF immunostaining was the most intense in RPE-Bruch's membrane-choriocapillaris complex. In AMD, PEDF was significantly lower in RPE cells, RPE basal lamina, Bruch's membrane and choroidal stroma. These data suggest that a critical balance exists between PEDF and VEGF, and PEDF may counteract the angiogenic potential of VEGF. The decrease in PEDF may disrupt the balance and be permissive for the formation of choroidal neovascularization (CNV) in AMD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019000      PMCID: PMC4932847          DOI: 10.1016/j.exer.2005.05.007

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  42 in total

1.  Morphological changes of retinal pigment epithelium and choroid in rd-mice.

Authors:  T Neuhardt; C A May; C Wilsch; M Eichhorn; E Lütjen-Drecoll
Journal:  Exp Eye Res       Date:  1999-01       Impact factor: 3.467

2.  Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.

Authors:  C Schwesinger; C Yee; R M Rohan; A M Joussen; A Fernandez; T N Meyer; V Poulaki; J J Ma; T M Redmond; S Liu; A P Adamis; R J D'Amato
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Authors:  D W Dawson; O V Volpert; P Gillis; S E Crawford; H Xu; W Benedict; N P Bouck
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

4.  Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF.

Authors:  K Ohno-Matsui; I Morita; J Tombran-Tink; D Mrazek; M Onodera; T Uetama; M Hayano; S I Murota; M Mochizuki
Journal:  J Cell Physiol       Date:  2001-12       Impact factor: 6.384

5.  Time-course expression of vascular endothelial growth factor as related to the development of the retinochoroidal vasculature in rats.

Authors:  X Yi; L C Mai; M Uyama; D T Yew
Journal:  Exp Brain Res       Date:  1998-01       Impact factor: 1.972

6.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Authors:  K Spilsbury; K L Garrett; W Y Shen; I J Constable; P E Rakoczy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

7.  VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Authors:  Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid.

Authors:  Sahng Yeon Kim; Carmen Mocanu; D Scott Mcleod; Imran A Bhutto; Carol Merges; Mark Eid; Patrick Tong; Gerard A Lutty
Journal:  Exp Eye Res       Date:  2003-10       Impact factor: 3.467

9.  Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells.

Authors:  A P Adamis; D T Shima; K T Yeo; T K Yeo; L F Brown; B Berse; P A D'Amore; J Folkman
Journal:  Biochem Biophys Res Commun       Date:  1993-06-15       Impact factor: 3.575

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  110 in total

Review 1.  Therapeutic targets in age-related macular disease.

Authors:  Alan C Bird
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

2.  Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.

Authors:  Bärbel Rohrer; Beth Coughlin; Mausumi Bandyopadhyay; V Michael Holers
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-06       Impact factor: 2.671

3.  A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions.

Authors:  Hui-Yuan Hou; Hong-Liang Liang; Yu-Sheng Wang; Zhao-Xia Zhang; Bai-Ren Wang; Yuan-Yuan Shi; Xiao Dong; Yan Cai
Journal:  Mol Ther       Date:  2010-07-20       Impact factor: 11.454

4.  VEGF 165 b in the developing vasculatures of the fetal human eye.

Authors:  Takayuki Baba; D Scott McLeod; Malia M Edwards; Carol Merges; Tanusree Sen; Debasish Sinha; Gerard A Lutty
Journal:  Dev Dyn       Date:  2012-01-31       Impact factor: 3.780

5.  Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling.

Authors:  Pranab K Mukherjee; Victor L Marcheselli; Sebastian Barreiro; Jane Hu; Dean Bok; Nicolas G Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

6.  Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization.

Authors:  Kyoungmin Park; Ji Jin; Yang Hu; Kevin Zhou; Jian-xing Ma
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

7.  Adhesion failures determine the pattern of choroidal neovascularization in the eye: a computer simulation study.

Authors:  Abbas Shirinifard; James Alexander Glazier; Maciej Swat; J Scott Gens; Fereydoon Family; Yi Jiang; Hans E Grossniklaus
Journal:  PLoS Comput Biol       Date:  2012-05-03       Impact factor: 4.475

8.  CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration.

Authors:  Daisuke Imai; Keisuke Mori; Kuniko Horie-Inoue; Peter L Gehlbach; Takuya Awata; Satoshi Inoue; Shin Yoneya
Journal:  J Ocul Biol Dis Infor       Date:  2010-07-28

9.  Activation of Rap1 inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization.

Authors:  Haibo Wang; Yanchao Jiang; Dallas Shi; Lawrence A Quilliam; Magdalena Chrzanowska-Wodnicka; Erika S Wittchen; Dean Y Li; M Elizabeth Hartnett
Journal:  FASEB J       Date:  2013-09-16       Impact factor: 5.191

10.  The mitochondria-targeted antioxidant SkQ1 restores αB-crystallin expression and protects against AMD-like retinopathy in OXYS rats.

Authors:  Natalia A Muraleva; Oyuna S Kozhevnikova; Anna A Zhdankina; Natalia A Stefanova; Tatyana V Karamysheva; Anzhella Z Fursova; Nataliya G Kolosova
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.